Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC)

MLA

Robin Katie Kelley, et al. “Assessment of Tumor Response, Alpha-Fetoprotein (AFP) Response, and Time to Progression (TTP) in the Phase III CELESTIAL Trial of Cabozantinib (C) versus Placebo (P) in Advanced Hepatocellular Carcinoma (HCC).” Annals of Oncology, vol. 29, Nov. 2018, p. ix46. EBSCOhost, https://doi.org/10.1093/annonc/mdy432.

APA

Robin Katie Kelley, Suvajit Sen, Debashis Sarker, Benjamin R. Tan, A-L Cheng, E. Banu, C. Love, Baek-Yeol Ryoo, H. Van Vlierberghe, Ghassan K. Abou-Alfa, Tim Meyer, Irfan Cicin, William P. Harris, Thomas Yau, Lorenza Rimassa, & Philippe Merle. (2018). Assessment of tumor response, alpha-fetoprotein (AFP) response, and time to progression (TTP) in the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (HCC). Annals of Oncology, 29, ix46. https://doi.org/10.1093/annonc/mdy432

Chicago

Robin Katie Kelley, Suvajit Sen, Debashis Sarker, Benjamin R. Tan, A-L Cheng, E. Banu, C. Love, et al. 2018. “Assessment of Tumor Response, Alpha-Fetoprotein (AFP) Response, and Time to Progression (TTP) in the Phase III CELESTIAL Trial of Cabozantinib (C) versus Placebo (P) in Advanced Hepatocellular Carcinoma (HCC).” Annals of Oncology 29 (November): ix46. doi:10.1093/annonc/mdy432.